Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage ...(us the relative risk of deathincreases b...),Health

Hyperphosphatemia is managed with a combination of dialysis, diet restriction, and phosphorus-binding agents, because diet and dialysis alone generally cannot adequately control phosphorus levels. Such binders "soak up" phosphorus in the gastrointestinal tract, before it can be absorbed into the blood, and aid patients in maintaining acceptable levels of mean serum phosphorus.

FOSRENOL

FOSRENOL is indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD).

FOSRENOL is an effective, noncalcium, nonresin phosphate binder that reduces high phosphorus levels in CKD Stage 5 patients. FOSRENOL is formulated as an easy-to-use, unflavored, chewable tablet that can be taken without water, an important consideration for CKD Stage 5 patients who must restrict their fluid intake.

FOSRENOL is available in a broad range of dosage strengths, including 500- mg, 750-mg and 1-g tablets. Patients taking FOSRENOL can achieve serum phosphorus target levels with as few as three tablets per day.*

FOSRENOL has the lowest pill burden of all phosphate binders, which may aid in adherence and reduce treatment costs.

The active ingredient in FOSRENOL is lanthanum, which has a high PBR. In addition, the binding power of FOSRENOL, in vitro, was not compromised by pH variations throughout the gastrointestinal tract.

FOSRENOL has a high affinity for phosphate and works by binding to dietary phosphorus in the gastrointestinal tract. Once bound, the FOSRENOL/phosphorus complex cannot pass into the bloodstream and is eliminated from the body, thereby decreasing mean serum phosphorus levels.

The safety of FOSRENOL has been studied in over 5,500 patients. Despite the challenge of CKD Stage 5 mortality for long-term data, a number of patients (N=22) taking FOSRENOL have been followed for more than 5 years. In addition, more than 87,000 patients have been prescribe
'/>"/>